Equity Overview
Price & Market Data
Price: $8.20
Daily Change: -$0.55 / 6.71%
Daily Range: $7.90 - $8.30
Market Cap: $13,167,264
Daily Volume: 7,211
Performance Metrics
1 Week: 37.71%
1 Month: -7.50%
3 Months: -36.32%
6 Months: -37.94%
1 Year: -30.28%
YTD: -35.14%
About Finch Therapeutics Group, Inc. (FNCHQ)
A snapshot of Finch Therapeutics Group, Inc. (FNCHQ)'s current market standing: priced at 8.20, with a daily adjustment of -$0.55 / 6.71%. Market cap at 13,167,264. Performance over the last 6 months (-37.94%) and YTD are particularly insightful.
Company Details
Employees: 1
Sector: Health services
Industry: Medical/Nursing services
Country: United States
Details
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.